利多卡因与胺碘酮对恶性室性心律失常疗效和安全性的系统评价  

System Evaluation about Effect and Safety of Lidocaine and Amiodarone on Patients with Malignant Ventricular Arrhythmia

作　　者：何洪静[1] 徐贵丽[1] 王慧敏[1] 邓琴[1] 邓婕[1] 

机构地区：[1]成都军区昆明总医院药剂科,昆明650032

出　　处：《中国药师》2008年第1期31-35,共5页China Pharmacist

摘　　要：目的:系统评价利多卡因与胺碘酮治疗严重室性心律失常的疗效及安全性。方法:通过电子检索5个数据库,纳入利多卡因与胺碘酮治疗严重室性心律失常的所有随机对照试验,逐个进行质量评价和资料提取,并进行Meta分析。结果:符合纳入标准的文章8篇,2个试验被排除;最后共6个试验包括674例患者符合纳入标准进入本系统评价。Meta分析结果显示:①总有效率:胺碘酮优于利多卡因(P<0.001);②病死率:差异无统计学意义(P>0.05);③药物不良反应发生率:利多卡因低于胺碘酮(P<0.05)。结论:本系统评价显示在治疗严重室性心律失常疗效方面,胺碘酮优于利多卡因;在降低患者病死率两者差异无统计学意义;在药物不良反应发生率方面,胺碘酮高于利多卡因。Objective： To evaluate the effect and safety of Lidocaine and Amiodarone on patients with malignant ventricular arrhythmia. Method： Five databases about Lidocaine and Amiodarone treated malignant ventricular arrhythmia were collected, and metaanalysis was performed. Result： After the titles and abstracts were readed, six trials which included 674 patients were performed system evaluation. The result of meta-analysis shown ： total effective rate, Lidocaine was worse than Amiodarone （ P〈0.001） ; fatality rate （P=0.61） ; ADR rate, Lidocaine was better than Amiodarone（P〉0.05 ）. Conclusion： On the aspect of treating malignant ventricular arrhythmia, Lidocaine is more inferior than Amiodarone ; on fatality rate, there are no statistical significance; on safety, Lidocaine is better than Amiodarone.

关 键 词：利多卡因 胺磺酮 恶性室性心律失常 系统评价 

分 类 号：R541.7[医药卫生—心血管疾病]